Philadelphia, Pennsylvania 19107

  • Hepatocellular Carcinoma


This study investigates if an experimental blood test can help predict how well cancer will remain under control with treatment. Ther experimental blood test involves measuring mircoRNAs. MicroRNAs are small molecules which help regulate how genes are expressed. This information may help researchers guide treatment for other patients in the future.


Inclusion Criteria: - Provide signed and dated informed consent form - Willing to comply with all study procedures and be available for the duration of the study - Definite diagnosis of hepatocellular carcinoma established (by standard radiographic or histologic criteria) - Felt to be reasonable candidate for liver transplantation, potentially contingent on success of down-staging therapy Exclusion Criteria: - Either active or recent solid organ cancer other than hepatocellur carcinoma (HCC) within the last 5 years, unless determined by transplant hepatology team not to represent contra-indication to liver transplantation - Contra-indication to LRT (as assessed by interventional radiologist, for example severe thrombocytopenia, severe vascular disease precluding access, etc) - History of prior liver transplantation - Active or prior systemic therapy for HCC



Primary Contact:

Jesse Civan, MD
Phone: 215-955-8900

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19107
United States

Jesse Civan
Phone: 215-955-8900

Site Status: Recruiting

Data Source:

Date Processed: June 19, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.